Skip to main content
TipRanks
Go Ultimate75% OFF

Medrx Co., Ltd. (4586) AI Stock Analysis

0 Followers
JP:4586

Medrx Co., Ltd.

(TSE/TYO:4586)

Select Model
Rating:39Underperform
Price Target:JPY 40.00â–²(5.26% Upside)
Action:reiterated
Date:11/03/26

Medrx Co., Ltd. receives a low overall score primarily driven by steep operating losses, aggressive cash burn, and a highly speculative valuation profile. While the company is protected by a flawless, debt-free balance sheet, the stock faces heavy selling pressure and trades in a severe technical downtrend, highlighting substantial risks for investors.

Positive Factors
Revenue reboundThe sharp 2025 revenue rebound shows that the company can expand its top line when development or commercialization activity improves. If this recovery is sustained, a larger revenue base could help absorb fixed operating costs and provide greater support for future product and partnership monetization.
Negative Factors
Persistent deep lossesThe company remains deeply unprofitable despite its strong gross margin, with expenses far exceeding the current revenue base. The deterioration in net margin suggests that revenue growth has not yet produced operating leverage, leaving profitability dependent on a substantial and sustained improvement in scale or cost structure.

Medrx Co., Ltd. (4586) vs. iShares MSCI Japan ETF (EWJ)

-80%-60%-40%-20%0%20%40%JP:4586-69.35%EWJ+16.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 2.77B
Dividend Yield
―
Average Volume (3M)
849.12K
Price to Earnings (P/E)
-2.8
Beta (1Y)
1.41
Revenue Growth
167.44%
EPS Growth
49.38%
Country
Japan
Employees
21
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Medrx Co., Ltd. Business Overview & Revenue Model

Company Description

Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption syste...

How the Company Makes Money

Medrx primarily makes money by monetizing its transdermal drug delivery technologies and related pharmaceutical products. Key revenue streams typically include: (1) licensing/out-licensing of developed transdermal formulations or drug candidates to p...

Medrx Co., Ltd. Financial Statement Overview

Summary

Financial health is severely dragged down by deep net income losses and high cash burn, despite a pristine, debt-free balance sheet with a zero Debt-to-Equity ratio.

Income Statement

25Negative

Balance Sheet

78Positive

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue121.00M128.08M257.92M29.53M59.48M8.35M
Gross Profit109.78M113.01M219.19M-18.43M10.45M-54.25M
EBITDA-868.59M-928.13M-754.62M-888.00M-1.05B-1.00B
Net Income-858.85M-937.37M-806.76M-932.90M-1.11B-1.06B
Balance Sheet
Total Assets1.74B2.16B2.27B2.05B1.40B2.11B
Cash, Cash Equivalents and Short-Term Investments1.14B1.75B1.98B1.72B994.02M1.70B
Total Debt000000
Total Liabilities149.79M108.54M107.00M127.52M185.56M153.10M
Stockholders Equity1.59B2.05B2.17B1.92B1.21B1.96B
Cash Flow
Free Cash Flow0-970.86M-803.00M-913.76M-1.08B-926.23M
Operating Cash Flow0-888.11M-803.00M-913.00M-1.07B-923.69M
Investing Cash Flow0-82.75M-3.15M-759.00K-1.96M-2.54M
Financing Cash Flow0745.09M1.07B1.64B356.31M815.91M

Medrx Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price38.00

Price Trends

50DMA53.76Negative
100DMA57.31Negative
200DMA74.23Negative

Market Momentum

MACD-4.89Positive
RSI22.91Positive
STOCH29.60Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4586, the sentiment is Negative. The current price of 38.00 is below the 20-day moving average (MA) of 45.50, below the 50-day MA of 53.76, and below the 200-day MA of 74.23, indicating a bearish trend. The MACD of -4.89 indicates Positive momentum. The RSI at 22.91 is Positive, neither overbought nor oversold. The STOCH value of 29.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4586.

Medrx Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4586 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4539JP:453947NeutralJPY 5.47B-11.24―3.30%0.31%-194.72%
JP:4582JP:458243NeutralJPY 5.95B-0.69――-30.58%6.93%
JP:4883JP:488343NeutralJPY 3.48B-1.41―――25.34%
JP:4892JP:489242NeutralJPY 5.19B-6.28――364.72%18.43%
JP:4597JP:459739UnderperformJPY 6.82B-7.89-53.06%―109.82%61.98%
JP:4586JP:458639UnderperformJPY 2.77B-2.81――167.44%49.38%

* Healthcare Sector Average

Performance Comparison

-50%0%50%JP:4586JP:4597JP:4539JP:4582JP:4883JP:4892Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4586 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4586Medrx Co., Ltd.38.00-90.00-70.31%
JP:4597Solasia Pharma KK25.00-8.00-24.24%
JP:4539Nippon Chemiphar Co., Ltd.1515.0034.182.31%
JP:4582Symbio Pharmaceuticals Limited59.00-47.00-44.34%
JP:4883Modalis Therapeutics Corporation30.00-37.00-55.22%
JP:4892Cyfuse Biomedical K.K.514.00-67.00-11.53%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 03, 2026